Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Johnson and Johnson
Mallinckrodt
QuintilesIMS
Chinese Patent Office
Express Scripts
Covington
Deloitte
Queensland Health

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021567

« Back to Dashboard

NDA 021567 describes REYATAZ, which is a drug marketed by Bristol Myers Squibb and is included in two NDAs. It is available from six suppliers. There are two patents protecting this drug and three Paragraph IV challenges. Additional details are available on the REYATAZ profile page.

The generic ingredient in REYATAZ is atazanavir sulfate. There are twenty-four drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the atazanavir sulfate profile page.
Summary for 021567
Tradename:REYATAZ
Applicant:Bristol Myers Squibb
Ingredient:atazanavir sulfate
Patents:2
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021567
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
REYATAZ atazanavir sulfate CAPSULE;ORAL 021567 NDA E.R. Squibb & Sons, L.L.C. 0003-3622 0003-3622-12 30 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0003-3622-12)
REYATAZ atazanavir sulfate CAPSULE;ORAL 021567 NDA E.R. Squibb & Sons, L.L.C. 0003-3624 0003-3624-12 60 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0003-3624-12)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrengthEQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Jun 20, 2003TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Dec 20, 2017Product Flag?Substance Flag?Delist Request?Y
Patent:➤ SubscribePatent Expiration:Jun 21, 2019Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 150MG BASE
Approval Date:Jun 20, 2003TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:Dec 20, 2017Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021567

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-001 Jun 20, 2003 ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-004 Oct 16, 2006 ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-003 Jun 20, 2003 ➤ Subscribe ➤ Subscribe
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-002 Jun 20, 2003 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
McKinsey
Johnson and Johnson
Boehringer Ingelheim
Fuji
Novartis
Accenture
Moodys
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot